Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: The HERA trial

Journal of Clinical Oncology

Volumn 27, Issue 18, 2009, Pages 2962-2969

  Dowsett, Mitch ^a   Procter, Marion ^a   McCaskill Stevens, Worta ^a   De Azambuja, Evandro ^a   Dafni, Urania ^a   Rueschoff, Josef ^a   Jordan, Bruce ^a   Dolci, Stella ^a   Abramovitz, Mark ^a   Stoss, Oliver ^a   Viale, Giuseppe ^a   Gelber, Richard D ^a   Piccart Gebhart, Martine ^a   Leyland Jones, Brian ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHROMOSOME 17; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; BREAST TUMOR; DISEASE FREE SURVIVAL; GENETICS; IMMUNOHISTOCHEMISTRY; MORTALITY; PHASE 3 CLINICAL TRIAL; PROTO ONCOGENE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; PROGNOSIS;

EID: 67649989634     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.7939     Document Type: Article

References (25)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
3. Akiyama T, Sudo C, Ogawara H, et al: The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646, 1986
4. Bartlett JM, Ellis IO, Dowsett M, et al: Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. J Clin Oncol 25:4423-4430, 2007
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
6. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
7. Slamon D, Eiermann W, Robert N, et al: BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACγT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACγTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006
8. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: FinHer Study Investigators: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006
9. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
10. Smith I, Procter M, Gelber RD, et al: HERA study team: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
12. Greenwood M: A report on the natural duration of cancer, in: Reports on Public Health and Medical Subjects (vol 33). London, United Kingdom, HM Stationery Office, 1926, pp 1-26
13. Konecny G, Pauletti G, Pegram M, et al: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95:142-153, 2003
14. Paik S, Kim C, Jeong J, et al: Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31. J Clin Oncol 25:5s, 2007 (suppl; abstr 511)
15. Perez EA, Romond EH, Suman VJ, et al: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/ without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 25:6s, 2007 (suppl; abstr 512)
16. Untch M, Gelber RD, Jackisch C, et al: Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 19:1090-1096, 2008
17. Arriola E, Marchio C, Tan DS, et al: Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 88:491-503, 2008
18. Di Leo A, Gancberg D, Larsimont D, et al: HER-2 amplification and topoisomerase IIα gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 8:1107-1116, 2002
19. Tanner M, Isola J, Wiklund T, et al: Scandinavian Breast Group Trial 9401: Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer. J Clin Oncol 24:2428-2436, 2006
20. Dowsett M, Hanna WM, Kockx M, et al: Standardization of HER2 testing: Results of an international proficiency-testing ring study. Mod Pathol 20:584-591, 2007
21. Kim C, Tang G, Baehner FL, et al: A comparison of estrogen receptor (ER) measurement by three methods in node-negative, estrogen receptor (ER)-positive breast cancer: Ligand binding (LB), immunohistochemistry (IHC), and quantitative RTPCR. Breast Cancer Res Treat 100:S295, 2006 (suppl 1; abstr 3116)
22. Paik S, Kim C, Wolmark N: HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358:1409-1411, 2008
23. Downs-Kelly E, Yoder BJ, Stoler M, et al: The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: A fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 29:1221-1227, 2005
24. Vanden Bempt I, van Loo P, Drijkoningen M, et al: Polysomy 17 in breast cancer: Clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 26:4869-4874, 2008
25. Reinholz MM, Jenkins RB, Hillman D, et al: The clinical significance of polysomy 17 in the HER2+ N9831 intergroup adjuvant trastuzumab trial. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007 (abstr 36)